Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2015

View Archived Issues

Prediction of tumor response to anti-PD-1 therapy in metastatic melanoma

Roche begins phase I study of RO-6927005 in solid tumors

Merck KGaA commences phase I trial of MSC-2490484A

First patient dosed in phase Ib trial of SYN-004 for the prevention of C. difficile infection

NephroGenex successfully completes QT study of Pyridorin

Warner Chilcott begins phase III study of sarecycline in acne vulgaris

Phase I study of intravenously administered BMS-986168 begins

GABA-A receptor modulation shows promising results for the treatment of autism spectrum disorders

Treatment ongoing in a phase I/II clinical trial of the antitumor RNAi therapeutic TKM-080301

Knight Therapeutics forms product commercialization partnership with NeurAxon

Preclinical investigation of a small-molecule JAK1/TYK2 inhibitor for psoriasis

MMP-3 may be a sex-specific marker of psychiatric disease

Researchers identify novel PS1 mutation involved in early-onset FAD

Shuttle Pharmaceuticals awarded NIH contract for novel radiation sensitizer in GI cancers

4D Pharma advances development of Blautix

United Therapeutics signs agreement with DEKA for development of Remodulin pump system

FDA approves trial protocol for Aethlon's Hemopurifier in patients infected with Ebola virus

Cempra reports results from phase III trial of solithromycin in bacterial pneumonia

Nav1.7 sodium channel blockers described in Amgen patents

Ferrer patents novel orexin OX2 receptor agonists

University of Texas System reports discovery of allosteric proteasome inhibitors

Antabio prepares and tests NDM-1 inhibitors for beta-lactam-resistant infections

Dual specificity protein kinase TTK inhibitors in early development at Bayer

Bristol-Myers Squibb identifies Factor VIIa inhibitors

Promising data revealed on rindopipemut for the treatment of relapsed glioblastoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 3, 2026